Abstract:Circulation: Genomic and Precision Medicine, Ahead of Print. Background:Predictive performance of polygenic risk scores (PRS) varies across populations. To facilitate equitable clinical use, we developed PRS for coronary heart disease (CHD; PRSCHD) for 5 genetic ancestry groups.Methods:We derived ancestry-specific and multi-ancestry PRSCHDbased on pruning and thresholding and continuous shrinkage priors (polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods) applied to summary statistics from the largest multi-ancestry genome-wide association study meta-analysis for CHD to date, including 1.1 million participants from 5 major genetic ancestry groups. Following training and optimization in the Million Veteran Program, we evaluated the best-performing PRSCHDin 176 988 individuals across 9 diverse cohorts.Results:Multi-ancestry polygenic risk score for CHD developed using pruning and thresholding methods and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods outperformed ancestry-specific Polygenic risk score for CHD developed using pruning and thresholding methods and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods across a range of tuning values. Two best-performing multi-ancestry PRSCHD(ie, polygenic risk score for CHD developed using pruning and thresholding methods optimized using a multi-ancestry population and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods optimized using a multi-ancestry population) and 1 ancestry-specific (PRSCSxEUR) were taken forward for validation. Polygenic risk score for CHD developed using pruning and thresholding methods (PT) optimized using a multi-ancestry population demonstrated the strongest association with CHD in individuals of South Asian genetic ancestry and European genetic ancestry (odds ratio per 1 SD [95% CI, 2.75 [2.41–3.14], 1.65 [1.59–1.72]), followed by East Asian genetic ancestry (1.56 [1.50–1.61]), Hispanic/Latino genetic ancestry (1.38 [1.24–1.54]), and African genetic ancestry (1.16 [1.11–1.21]). Polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods optimized using a multi-ancestry population showed the strongest associations in South Asian genetic ancestry (2.67 [2.38–3.00]) and European genetic ancestry (1.65 [1.59–1.71]), lower in East Asian genetic ancestry (1.59 [1.54–1.64]), Hispanic/Latino genetic ancestry (1.51 [1.35–1.69]), and the lowest in African genetic ancestry (1.20 [1.15–1.26]).Conclusions:The use of summary statistics from a large multi-ancestry genome-wide meta-analysis improved the performance of PRSCHDin most ancestry groups compared with single-ancestry methods. Despite the use of one of the largest and most diverse sets of training and validation cohorts to date, improvement of predictive performance was limited in African genetic ancestry. This highlights the need for larger Genome-wide association study datasets of underrepresented populations to enhance the performance of PRSCHD.

Clinical Utility of Polygenic Scores for Cardiometabolic Disease in Arabs

Polygenic risk score portability for common diseases across genetically diverse populations

Ancestry-aligned polygenic scores combined with conventional risk factors improve prediction of cardiometabolic outcomes in African populations

Polygenic risk scores for the prediction of cardiometabolic disease

The current state and future of cardiometabolic polygenic risk scores in European and non-European population cohorts

Metabolic Polygenic Risk Scores for Prediction of Obesity, Type 2 Diabetes, and Related Morbidities

Validity of European-centric cardiometabolic polygenic scores in multi-ancestry populations

Polygenic scores for longitudinal prediction of incident type 2 diabetes in an ancestrally and medically diverse primary care physician network: a patient cohort study

Utility of polygenic scores across diverse diseases in a hospital cohort for predictive modeling

Polygenic Risk Score Assessment for Coronary Artery Disease in Asian Indians

Current State and Future of Polygenic Risk Scores in Cardiometabolic Disease: A Scoping Review

Abstract P339: The Clinical Application and Ancestral Diversity of Cardiometabolic Polygenic Risk Scores

Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers

Genomic Prediction of 16 Complex Disease Risks Including Heart Attack, Diabetes, Breast and Prostate Cancer

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

Clinical use of polygenic risk scores for detection of peripheral artery disease and cardiovascular events

Polygenic Risk Scores in Predicting Coronary Artery Disease in Symptomatic Patients. A Validation Study

Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse Genome-Wide Association Study and Population-Specific Optimization

The personal and clinical utility of polygenic risk scores

Population Performance and Individual Agreement of Coronary Artery Disease Polygenic Risk Scores

Polygenic Prediction of Type 2 Diabetes in Africa